Sollis Therapeutics, a Columbus, Ohio-based clinical-stage biotechnology company, received an up to $50m investment.
The total equity financing was led by from Deerfield Management.
The company intends to use the funds for the development of an innovative non-opioid and non-steroid solution for pain associated with sciatica and other neuropathic pain syndromes through FDA approval.
Led by Gregory Fiore, MD, CEO, Sollis Therapeutics is a Columbus Ohio based clinical-stage biotechnology company focused on developing novel non-steroid, non-opioid analgesics. The company’s first product is an extended release combination analgesic and anti-inflammatory medication purpose-built for targeted local delivery for the treatment of sciatica and other neuropathic pain syndromes.
The product will soon be entering into a pivotal clinical trial at multiple centers throughout the United States.
FinSMEs
13/04/2018